ACT 4 Children shared a post on LinkedIn:
“Did you know that children in low- and middle-income countries (LMIC) face up to 7 times higher prices for essential pediatric cancer medicines compared to those in high-income countries (HIC)?
Source – NCDconnect
These disparities continue even in research. While 70% of pediatric cancer clinical trials are conducted in HICs, LMICs account for just 6%, leaving children in these regions with fewer options for innovative treatments.
Providing sustainable access to high-quality curative medicines is a core pillar of what we do at ACT 4 Children. Follow and NCDconnect to play your part and help close the global health equity gap in pediatric cancer.”
More posts featuring ACT 4 Children.